View Report
January 12, 2026
Batch: GAPE2212
Measured Result 11.04 mg 110.4% of label claim
Peptide Hubs
Peptide Hubs
Latest Laboratory Result 11.04 mg January 12, 2026 · 110.4% of label claim View
You will save $18.00
PE 22-28 10 mg
Product Information Compound Details
Active Substance PE 22-28 Spadin-derived heptapeptide TREK-1 inhibitor
10 mg/vialStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$27.00
$45.00
Shipping :
International
U.S. Domestic
Product Overview
PE 22-28 10 mg by Peptide Hubs
PE 22-28 10 mg is a lyophilized spadin-derived heptapeptide research product manufactured by Peptide Hubs and supplied as a 10 mg/vial powder in a 2 mL vial.
PE 22-28 Injectable
PE 22-28 10 mg contains PE 22-28, a synthetic seven-amino-acid peptide derived from spadin, an endogenous peptide that acts as a specific blocker of the TREK-1 potassium channel. PE 22-28 was developed as an optimized analog of spadin, demonstrating improved TREK-1 inhibition with an IC50 of 0.12 nM compared to 40–60 nM for spadin, along with greater in vivo stability and extended duration of action.
PE 22-28 works by binding to and blocking the TREK-1 (TWIK-related potassium channel-1) channel, a two-pore domain potassium channel expressed predominantly in the prefrontal cortex and hippocampus, brain regions involved in mood regulation, memory, and learning. TREK-1 overactivity has been associated with depressive states, partly through its regulation of serotonin release and neuroplasticity. In preclinical research, PE 22-28 has been shown to induce hippocampal neurogenesis after only a four-day treatment and to enhance synaptogenesis, measured by increased PSD-95 expression in mouse cortical neurons.
PE 22-28 is not FDA-approved for any human indication. As of April 2026, a PubMed search for PE-22-28 human studies returns zero results, and a comprehensive review of the TREK-1 blocker program explicitly acknowledges that no human pharmacokinetic or safety data exists. In non-medical research contexts, PE 22-28 is referenced for its potential rapid-onset antidepressant-like and neurogenic effects observed in rodent models, though such use falls outside approved indications and lacks clinical validation.
Key Benefits of PE 22-28 10 mg
- Spadin-derived heptapeptide TREK-1 inhibitor with high affinity (IC50 0.12 nM)
- Lyophilized powder format for reconstitution flexibility
- Studied in preclinical models for rapid neurogenesis and synaptogenesis
- 10 mg per vial for research protocols
- Manufactured by Peptide Hubs
Formulation
Lyophilized Powder
PE 22-28 10 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. Reconstitution with an appropriate solvent is required before use in research contexts.
Product Profile
PE 22-28 Profile
PE 22-28 is a synthetic heptapeptide with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg and a molecular weight of approximately 773.9 Da.
TREK-1 Channel Inhibitor
PE 22-28 belongs to the class of spadin-derived peptides, which are synthetic analogs of an endogenous peptide generated from the post-translational maturation of sortilin. Unlike typical research peptides that act through receptor binding, PE 22-28 functions by directly blocking the TREK-1 potassium channel, a mechanosensitive and thermosensitive channel that regulates neuronal excitability and neurotransmitter release.
In vitro studies using patch-clamp techniques on human TREK-1 expressed in HEK cells demonstrated that PE 22-28 has a better specificity and affinity for the TREK-1 channel compared to spadin, with an IC50 of 0.12 nM versus 40–60 nM for spadin. The peptide is selective for TREK-1 over other related potassium channels including TREK-2, TRAAK, TRESK, and TASK-1 at concentrations up to 100 nM. In vivo, PE 22-28 has demonstrated antidepressant-like effects in rodent behavioral models including the forced swimming test and novelty-suppressed feeding test, with effects lasting up to 23 hours after a single administration compared to 7 hours for spadin.
In non-medical bodybuilding contexts, PE 22-28 is primarily referenced for its potential cognitive and mood-related effects rather than for physique enhancement. Community protocols commonly reference intranasal or subcutaneous administration at 100–400 mcg once daily.
Defining Characteristic
Rapid Neurogenesis in Preclinical Models
PE 22-28 is distinguished by its ability to induce hippocampal neurogenesis after only four days of treatment in mice, substantially faster than conventional antidepressants which typically require weeks to stimulate measurable neurogenic activity.
PE 22-28 10 mg vs Other Peptide Hubs Preparations
Peptide Hubs offers several research peptides targeting different neurological and physiological systems. Within this lineup, Semax is commonly discussed alongside PE 22-28 for its cognitive and neuroprotective effects, though Semax operates through modulation of the Ras/ERK signaling pathway rather than TREK-1 channel blockade.
For research focused on sleep and circadian rhythms rather than mood and cognition, DSIP represents a different approach entirely. For research requiring a reconstitution solution, Bacteriostatic Water is the standard diluent for preparing lyophilized peptides like PE 22-28 10 mg.
Laboratory Testing
PE 22-28 10 mg Lab Reports
Published laboratory reports for PE 22-28 10 mg are shown below with the test date, measured content, and batch number.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
PE 22-28 10 mg Dosage & Usage
The information below is provided for educational reference only. PE 22-28 is not an FDA-approved human drug. Its use for any non-medical purpose falls outside approved indications, and no established human dosing regimen exists.
Typical Dosage Ranges
Because PE 22-28 lacks FDA approval and human clinical trials, there is no medically established dosage range. All published dosing data is derived from preclinical mouse studies using intraperitoneal administration. Community protocols have extrapolated from these animal studies to intranasal and subcutaneous routes.
| Use Case | Common Reference Range | Administration |
|---|---|---|
| Preclinical mouse study (acute) | 3–4 mcg/kg | Intraperitoneal, single dose |
| Preclinical mouse study (sub-chronic) | 3–4 mcg/kg/day × 4 days | Intraperitoneal |
| Community protocol (non-medical) | 100–400 mcg | Intranasal or subcutaneous, once daily |
| Community conservative start | 100 mcg | Titrate based on response |
Preclinical studies used extremely low doses (microgram per kilogram range) reflecting the peptide's high potency at TREK-1. Community users employ fixed doses of 100–400 mcg, with some reports suggesting staying under 500–600 mcg to avoid lethargy. No dose-response studies or maximum tolerated dose studies have been published for humans.
Reconstitution & Handling
PE 22-28 10 mg is supplied as a lyophilized powder and requires reconstitution before use. Typical research concentrations range from 0.1 to 1 mg/mL when reconstituted in sterile water or bacteriostatic water.
Reconstituted solution should be stored refrigerated at 2–8°C and used within 4 weeks, or aliquoted and frozen at -20°C. Avoid repeated freeze-thaw cycles.
Stacking & Cycle Considerations
In non-medical research contexts, PE 22-28 is sometimes discussed in combination with other cognitive peptides such as Semax or Pinealon, though no clinical evidence supports such combinations. Community protocols reference cycle lengths of 4–8 weeks with 1-week breaks between cycles.
Important
Individual Response Varies
No human pharmacokinetic or dose-response data exists for PE 22-28. All dosage information is derived from preclinical animal studies or community convention and should not be interpreted as medical guidance.
Safety & Information
PE 22-28 Safety Information
PE 22-28 is not FDA-approved for any human use. No human pharmacokinetic, safety, or efficacy studies have been conducted.
Important Safety Information
PE 22-28 has not received FDA approval and has never been tested in humans. A comprehensive 2019 review of the TREK-1 blocker program explicitly acknowledges that no human pharmacokinetic, safety, or efficacy data exists. The peptide is a preclinical research compound only.
An important counterpoint in the scientific literature comes from studies examining TREK-1 in vascular and neuroinflammatory contexts. Research has shown that TREK-1 deficiency can worsen blood-brain barrier damage and neuroinflammation after intracerebral hemorrhage, and that TREK-1 promotes blood-brain barrier breakdown and neuronal death after focal cerebral ischemia. These findings indicate that TREK-1's role in the brain is region-specific and context-dependent, and chronic blockade could plausibly carry risks in certain neurovascular settings that rodent depression models would not detect.
Important
Non-Medical Use
PE 22-28 is sold strictly as a research chemical for laboratory use only. It is not intended for human consumption, medical treatment, or veterinary applications. Non-medical use falls outside approved indications.
Potential Adverse Effects
No rodent toxicology data specific to PE 22-28 is publicly available in peer-reviewed form. Community reports describe lethargy or excessive sedation as the most commonly reported side effect, particularly at doses above 500–600 mcg, possibly related to the mechanism of TREK-1 channel blockade affecting neuronal excitability.
The standard limitations of preclinical depression research apply: forced swim and tail suspension tests measure behavioral despair in rodents as proxies for antidepressant activity, but these assays have a high false-positive rate and a poor historical record of predicting human clinical outcomes. Rodent neurophysiology, plasma pharmacokinetics, and blood-brain barrier properties differ substantially from those in humans.
Conditions Requiring Medical Evaluation
Given the complete absence of human safety data, any consideration of PE 22-28 use should involve consultation with a qualified healthcare professional. The region-specific and context-dependent role of TREK-1 in the brain suggests that chronic blockade could carry risks that are not well characterized.
Monitoring During Use
No established monitoring protocol exists for PE 22-28. In research contexts, any adverse reactions should be documented and reported to appropriate authorities. Suggested baseline bloodwork in community protocols includes CBC with differential and comprehensive metabolic panel.
Product Care
Storage & Handling
Store lyophilized powder at -20°C, protected from light and moisture. Reconstituted solutions should be refrigerated at 2–8°C and used within 4 weeks, or aliquoted and frozen at -20°C. Keep out of reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
PE 22-28 10 mg is supplied through the official Peptide Hubs distribution chain and shipped in original manufacturer packaging with discreet handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official Peptide Hubs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your PE 22-28 10 mg product, use the security code on the vial label and cross-check it on the Peptide Hubs official site. Original packaging and manufacturer presentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
PE 22-28 10 mg Storage
Proper storage conditions help preserve peptide stability and integrity throughout shelf life.
Recommended Conditions
Store lyophilized powder at -20°C, protected from light and moisture. Under these conditions, the dry powder is stable for extended periods.
Once reconstituted, store refrigerated at 2–8°C and use within 4 weeks, or aliquot and freeze at -20°C. Avoid repeated freeze-thaw cycles to maintain peptide integrity.
Keep out of reach of children. Follow proper handling practices.
Quick Reference
Do & Don't
- Do store powder at -20°C, protected from light and moisture
- Do keep in original packaging until use
- Do refrigerate reconstituted solution at 2–8°C
- Don't expose to excessive heat or moisture
- Don't subject to repeated freeze-thaw cycles
- Don't use if solution appears cloudy or contains particles
Frequently Asked Questions
PE 22-28 10 mg FAQ
Answers to common questions about PE 22-28 10 mg, spadin-derived peptides, and research compound handling.
What is PE 22-28 10 mg used for?
PE 22-28 10 mg is a research peptide studied in preclinical models for its TREK-1 channel inhibitory effects and potential rapid-onset antidepressant-like activity. In non-medical contexts, it is referenced for cognitive and mood-related research, though such use falls outside approved indications and lacks human clinical validation.
How often should PE 22-28 10 mg be injected?
No established human dosing schedule exists. Preclinical mouse studies used intraperitoneal injection once daily for 4 days. Community protocols commonly reference intranasal or subcutaneous administration once daily at 100–400 mcg, but this is based on convention rather than clinical data.
Does PE 22-28 10 mg require PCT?
PE 22-28 does not suppress endogenous testosterone production and does not require post-cycle therapy in the way anabolic steroids do. However, any non-medical peptide use should be approached with caution given the complete absence of human safety data.
What does PE 22-28 do?
PE 22-28 is a spadin-derived heptapeptide that blocks the TREK-1 potassium channel with high affinity (IC50 0.12 nM). In preclinical models, it induces hippocampal neurogenesis after only four days and enhances synaptogenesis, effects associated with rapid antidepressant-like activity.
How long does PE 22-28 take to work?
Preclinical research demonstrated that PE 22-28 induces neurogenesis after only four days of treatment in mice, substantially faster than conventional antidepressants which typically require weeks. The peptide's duration of action after a single dose was reported as up to approximately 23 hours, compared to 7 hours for spadin.
Is PE 22-28 the best TREK-1 inhibitor?
There is no universally “best” TREK-1 inhibitor. PE 22-28 is a potent and selective inhibitor with an IC50 of 0.12 nM, demonstrating better specificity and affinity for TREK-1 compared to its parent compound spadin. However, no human comparative data exists.
What is the difference between PE 22-28 10 mg and Semax?
PE 22-28 acts by blocking the TREK-1 potassium channel, while Semax modulates the Ras/ERK signaling pathway. They operate through entirely different mechanisms and address different aspects of neurobiology.
What is the difference between PE 22-28 10 mg and DSIP?
PE 22-28 targets mood and neuroplasticity through TREK-1 channel inhibition, while DSIP is studied for sleep architecture modulation. They operate through different biological systems and are not interchangeable.
Is 400 mcg of PE 22-28 a lot?
400 mcg is within the upper range commonly referenced in community protocols (200–400 mcg). Preclinical mouse studies used much lower weight-based doses (3–4 mcg/kg), and no human dose-response data exists. Community reports suggest staying under 500–600 mcg to avoid lethargy.
What strength is PE 22-28 10 mg?
PE 22-28 10 mg is labeled at 10 mg of PE 22-28 per vial. It is supplied as a lyophilized powder in a 2 mL vial.
Is PE 22-28 10 mg lab tested?
Yes. A published laboratory report dated January 12, 2026 measured PE 22-28 10 mg at 11.04 mg, equivalent to 110.4% of its 10 mg label claim. The batch number is GAPE2212.
How should PE 22-28 10 mg be stored?
Store the lyophilized powder at -20°C, protected from light and moisture. Once reconstituted, refrigerate at 2–8°C and use within 4 weeks, or aliquot and freeze at -20°C.
Related Offers
Lab Tested
Shipped International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Semax Synthetic ACTH(4-10) analogue heptapeptide
10 mg/vialStrength 10 mg/vial
Package 1 Vial 2 mL vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$42.00
$70.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance GHK-CU Copper Tripeptide-1 (Glycyl-L-Histidyl-L-Lysine Copper)
50 mg/vialStrength 50 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$27.00
$45.00
Shipped International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Pinealon Synthetic tripeptide (Glu-Asp-Arg / EDR)
20 mg/vialStrength 20 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$33.00
$55.00
Lab Tested
Shipped International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Chonluten Tripeptide (Glu-Asp-Gly / EDG)
20 mg/vialStrength 20 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$27.00
$45.00